

Short Curriculum Vitae

First and Last Name: Ziad A. Massy

ORCID identifier: 0000-0001-5771-5996

Address: Service de Néphrologie, Hôpital Ambroise Paré, 9 av. Charles de Gaulle, 92100 Boulogne Billancourt cedex, France

Phone : + 33 1 4909 5635 ; Fax : + 33 1 4909 5050 ; Email : ziad.massy@aphp.fr

Current professional functions: Professor of Nephrology (Rank Excellent level) and Head of the Division of Nephrology at Paris West University (UVSQ)-Ambroise Paré Hospital, Paris, and Co-Director of Research laboratory INSERM Unit 1018 at UVSQ, Versailles, France

Academic Cursus and Professional Experience

- Since January 1, 2015: Co-Director of Research laboratory Unit INSERM U-1018 at the UVSQ, Versailles, France
- Since September 1, 2012: Professor of Nephrology and Head of the Division of Nephrology at Paris Ouest University (UVSQ) - Ambroise Paré Hospital, Boulogne Billancourt (Paris), France
- 2005-2014: Director of Research laboratory INSERM Unit 1088 at University of Picardie Jules Verne (UPJV), Amiens, France
- From May 3, 2010 to September 1, 2012: Vice Research Director at Amiens University Hospital
- From January 1, 2008 to September 1, 2012: Coordinator of Clinical Research Centre, Amiens University hospital
- From September 1, 2003 to September 1, 2012: Full Professor of Pharmacology at UPJV, Staff Physician at Nephrology Division, Amiens University Hospital
- 2002-2003: Associate Professor of Pharmacology, UPJV, Staff Physician at Nephrology Division, Amiens University Hospital
- 2001: Research Habilitation, UPJV, Amiens
- 2000: PhD, Paris-V University, Paris
- 1996-2002: Clinical practioner, Nephrology Division, Beauvais hospital, Beauvais, and Research associate, INSERM Units 90 and then 507, Necker Hospital, Paris, France
- 1994-1996: Research fellow at Division of Nephrology, Department of Medicine, and Minnesota Medical Research Foundation, Hennepin County Medical Centre, University of Minnesota, Minneapolis, Minnesota, USA
- 1991-1994: Clinical practioner, Nephrology Division, Beauvais Hospital, Beauvais, and Research associate, INSERM Unit 90, Necker Hospital, Paris.
- 1989-1990: Assistant ('Chef de Clinique-Assistant'), Renal Transplant Division, Necker Hospital, Paris.
- 1986-1989: Fellow, and awarded fellow at Nephrology Department and Urinary Radiology Division, Necker Hospital, Paris.
- 1986: Certificate of Specialization (CES) in Nephrology, Paris-V University Medical School, Paris
- 1982-1986: Resident in Internal Medicine, Intensive Care and Nephrology-Dialysis Divisions at 2 University Hospitals: Necker hospital, Paris, and Amiens University Hospital, Amiens.

Awards

- Hungarian Society of Nephrology Korany Award, 2015
- Fondation du Rein Award, 2010
- Société de Néphrologie-Amgen grant, Oct 2006 (Title : ‘Etude de la circulation cérébrale chez la souris invalidée pour le gène de l’apolipoprotéine E avec et sans insuffisance rénale’)
- Young Investigator Award from the National Kidney Foundation of the Upper Midwest, 1995 (Project entitled: ‘Role of dolichol in mesangial cell proliferation’).

Editorial Boards

- Toxins (**Editorial board from 2017 to 2019**)
- Brazilian Journal of Nephrology (**Editorial board since 2015**)
- Journal of the Egyptian Society of Nephrology and Transplantation (**Editorial board since 2015**)
- Kidney International (**Editorial board since 2009**)
- BANTAO Journal (**Editorial board since 2009**)
- Néphrologie et Thérapeutique (**Editorial board since 2005, Editor in Chief from 2007 until Oct 2010**).
- Journal of Nephrology (**Editorial board since 2004**)
- Nephron-Clinical Practice (**Editorial board from 2003 to 2008**)
- Journal of Renal Nutrition (**Editorial board since 2003**)
- Nephrology Dialysis Transplantation-Educational ([www.NDT-Educational.org], **Editorial board 2002 -2014**)
- Nephrology Dialysis Transplantation (**Editorial board since 1999**)
- Hypertension Dialysis and Clinical Nephrology ([www.hdcn.com], **Editorial board since 1997**)

Scientific Societies and Working Groups

- Since May 2017, **Clinical and Nephrology Governance Chair, ERA EDTA**
- Since May 2015, **Chairman of the European Registry, ERA-EDTA**
- Since May 2011, member of the **ERA-EDTA** Council, former Chair of the ERA-EDTA International Committee (until May 2013)
- January 2016 –December 2018, member of the **KDIGO Executive Committee**
- Since 2013 member of **CKDDOPPS steering Committee**
- Since 2012 member of **DOPPS steering Committee**
- Since Oct 2012, Core-member and then Advisor of the **CKD-MBD WG** Working Group Advisory Board
- Sept 2010 – Dec 2014, Board of the Council of **EVBO** (European Vascular Biology Organisation)
- Since June 2010, Core-member of **EURECAM** (European REnal and CArdiovascular MEdicine) and then Advisor Working Group Advisory Board
- From 2008 to 2011, **Co-Chairman of European Uremic Toxins (EUTox)** group
- Since 1999: Member of **EUTox** group
- From 2003 to 2012, Member of the French Society of Pharmacology
- Since 2002, Member of ERA-EDTA
- Since 1995, Member of the American Society of Nephrology
- Since 1994, Member of the International Society of Nephrology
- Since 1990, Member of the French Society of Nephrology and **member of Council (2008 -2014 and 2017 – until now)**

H Index via Publish or Perish v6: 81 or Index H via Web of Sciences: 69, Key words massy z or massy za]] – Total Number of Publications, Medline March 2021: 540

Selected Recent Publications

1. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, Collart F, Hemmeler MH, Ambühl P, Kerschbaum J, Legeai C, Del Pino Y Pino MD, Mircescu G, Mazzoleni L, Hoekstra T, Winzeler R, Mayer G, Stel VS, Wanner C, Zoccali C, **Massy ZA**. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. . *Kidney Int.* 2020c;98(6):1540-1548.
2. Villain C, Metzger M, Combe C, Fouque D, Frimat L, Jacquelinet C, Laville M, Briançon S, Klein J, Schanstra JP, Robinson BM, Mansencal N, Stengel B, **Massy ZA**. Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. *Nephrol Dial Transplant.* 2020;35(5):827-836
3. Dargelos M, Couturier A, Ferlicot S, Goujon JM, Roque-Afonso AM, Gault E, Touchard G, Ory C, Kaaki S, Vilaine E, Essig M, **Massy ZA**. Severe acute respiratory syndrome coronavirus 2 indirectly damages kidney structures. . *Clin Kidney J.* 2020 Dec 14;13(6):1101-1104.
4. Liabeuf S, Laville SM, Glorieux G, Cheddani L, Brazier F, Titeca Beauport D, Valholder R, Choukroun G, **Massy ZA**. Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. *Int J Mol Sci.* 2020; 21(6):2031
5. Liabeuf S, McCullough K, Young EW, Pisoni R, Zee J, Reichel H, Pecoits-Filho R, Port FK, Stengel B, Csomor PA, Metzger M, Robinson B, **Massy ZA**. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps. *Bone* 2019;129:115058
6. Massy ZA, Caskey FJ, Finne P, Harambat J, Jager KJ, Nagler E, Stengel B, Sever MS, Vanholder R, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Soler MJ, Rychlík I, Spasovski G, Stevens K, Wanner C, Zoccali C. Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. *Nephrol Dial Transplant* 2019;34:1469-1480
7. Hénaut L, Grissi M, Brazier F, Assem M, Poirot-Leclercq S, Lenglet G, Boudot C, Avondo C, Boullier A, Choukroun G, **Massy ZA**, Kamel S, Chillon JM. Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease. *Sci Rep* 2019; 23;9:6432
8. Pecoits-Filho R, Fliser D, Tu C, Zee J, Bieber B, Wong MMY, Port F, Combe C, Lopes AA, Reichel H, Narita I, Stengel B, Robinson BM, **Massy Z**; CKDopps Investigators. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. *J Clin Hypertens (Greenwich)* 2019;21:991-100
9. Liabeuf S, Sajjad A, Kramer A, Bieber B, McCullough K, Pisoni R, Caskey F, Combe C, Robinson BM, Jager KJ, **Massy ZA**. Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS). *Nephrol Dial Transplant* 2019;34:2105-2110
10. Villain C, Metzger M, Combe C, Fouque D, Frimat L, Jacquelinet C, Laville M, Briançon S, Klein J, Schanstra JP, Robinson BM, Mansencal N, Stengel B, **Massy ZA**; Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Investigators. Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. **Nephrol Dial Transplant** 2018 Aug 28 [Epub ahead of print]
11. Aleksinskaya MA, Monge M, Siebelt M, Slot EM, Koekkoek KM, de Bruin RG, **Massy ZA**, Weinans H, Rabelink TJ, Fibbe WE, Jan van Zonneveld A, van Pel M. Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche. **Sci Rep** 2018;8(1):15385

12. Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, **Massy ZA**, Ortiz A, Rossignol P, Wiecek A, Zoccali C, London GM; European Renal Association European Dialysis; Transplant Association (ERA-EDTA) European Renal; Cardiovascular Medicine (EURECA-m) working group. Clinical management of the uraemic syndrome in chronic kidney disease. **Lancet Diabetes Endocrinol**. 2016 Apr;4(4):360-73
13. Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, **Massy ZA**. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. **Nephrol Dial Transplant**. 2016 May 4
14. Rossignol P, **Massy ZA**, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D; ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network. The double challenge of resistant hypertension and chronic kidney disease. **Lancet** 2015 Oct 17;386(10003):1588-98
15. Liabeuf S, Desjardins L, Diouf M, Temmar M, Renard C, Choukroun G, **Massy ZA**. The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease. **PLoS One** 2015 Jul 16;10(7):e0131707
16. Gross P, **Massy ZA**, Henaut L, Boudot C, Cagnard J, March C, Kamel S, Drueke TB, Six I. Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling. **J Cell Physiol** 2015 Dec;230(12):2927-35
17. Six I, Okazaki H, Gross P, Cagnard J, Boudot C, Maizel J, Drueke TB, **Massy ZA**. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. **PLoS One** 2014 Apr 2;9(4):e93423
18. Barreto FC, de Oliveira RB, Benchitrit J, Louvet L, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Riser BL, **Massy ZA**. Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease. **J Bone Miner Metab** 2014 Nov;32(6):636-44
19. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, **Massy ZA**, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. **Lancet**. 2011;377(9784):2181-92
20. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, **Massy ZA**. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. **Kidney Int** 2010; 77: 550-6
21. Maizel J, Six I, Slama M, Tribouilloy C, Sevestre H, Poirot S, Giummelly P, Atkinson J, Choukroun G, Andrejak M, Kamel S, Mazière JC, **Massy ZA**. Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. **Circulation** 2009 20;119(2):306-13
22. Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drüeke TB, **Massy ZA**. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE^{-/-}) mice. **Atherosclerosis** 2009;205(1):55-62
23. Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, Walden M, Kaiser T, Mischak H, Drüeke TB, Lacour B, **Massy ZA**. Effects of oral vitamin C supplementation in hemodialysis patients - a proteomic assessment. **Proteomics** 2006;6(3):993-1000
24. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov I, Vanholder R, Lacour B, Drüeke TB, **Massy ZA**. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E deficient (apoE^{-/-}) mice **Circulation** 2005; 112;2875-2822
25. **Massy ZA**, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. **J Am Soc Nephrol** 2005;16(1):109-16.